BIOT
Unmatched Productivity and Seamless Scalability: Advantages of the XCell® ATF System for Upstream Process Intensification
📌 The XCell® ATF system offers unmatched productivity and seamless scalability for upstream process intensification. 📌 This system is advantageous for bioprocessing upstream, including culturing of animal or microbial cells. 📌 The system uses controlled feeding, aerating, and process strategies in different vessel types. 📌 It also provides options for assays, bioreactors, cell culture media, and expression platforms, among others. 📌 Downstream processing involves removing contaminants through centrifugation, filtration, and chromatographic technologies. 📌 The XCell® ATF system offers advantages in downstream processing, such as filtration, separation/purification, and viral clearance. 📌 The system is also beneficial for manufacturing drug products, including biosimilars and cell/gene therapies. 📌 Analytical technologies are used to characterize biological products, manufacturing processes, and raw materials. 📌 The XCell® ATF system supports analytical applications for culture development, cell line development, and product characterization. 📌 The system is advantageous for businesses in the biopharmaceutical industry, providing support for careers, economics, and regulatory affairs. ⚡️ In summary, the XCell® ATF system offers productivity and scalability benefits for bioprocessing, including upstream and downstream processing, manufacturing, analytical applications, and business support.
UK doubles CGT workforce but talent shortage still a threat
📰 The UK has doubled its Capital Gains Tax (CGT) workforce to tackle tax evasion and avoid a talent shortage. 👥 Despite the increase, there is still a concern about a lack of skilled professionals. 💼 The expansion aims to address the growing complexity of tax issues and improve compliance. 💰 This move demonstrates the government's commitment to fighting tax evasion and ensuring a fair tax system. ⚖️ Stricter enforcement and tougher penalties are expected to deter tax evasion.
Bio-Techne takes aim at CGT analytical bottlenecks
🔵 Bio-Techne is targeting bottlenecks in the analytical process for cell and gene therapy development. 🔵 The company aims to provide solutions to improve efficiency and speed up the development of these therapies. 🔵 Analytical processes play a crucial role in ensuring the safety and quality of cell and gene therapies. 🔵 Bio-Techne's focus on addressing bottlenecks in this area will help in advancing the field of regenerative medicine.
Bluebird bio receives US FDA nod for sickle cell therapy
📢 Bluebird bio has received approval from the US FDA for its sickle cell therapy. 💉 This therapy, called LentiGlobin, is a gene therapy that aims to treat sickle cell disease. 🩸 Sickle cell disease is a genetic condition that affects the shape and function of red blood cells. 👨⚕️ The treatment involves modifying the patient's own stem cells to produce healthy red blood cells. 🗓️ The approval is based on positive results from clinical trials showing efficacy and safety. 🌍 This therapy offers hope for patients with sickle cell disease, who currently have limited treatment options.
Abzena taps into ProteoNic’s viral vector tech
🔍 Abzena has partnered with ProteoNic to use its viral vector technology in the development of biotechnology products. 🧬 This technology is used to deliver genetic material into cells, making it an important tool in gene therapy and biopharmaceutical manufacturing. 💉 The partnership will allow Abzena to enhance its capabilities in viral vector manufacturing and offer a more efficient and streamlined process for its clients. 🚀 This collaboration highlights the growing importance of viral vector technology in the biotech industry.
Gene therapy firm Locanabio to close by end of 2023
⚠️ Gene therapy firm Locanabio will close by the end of 2023. 🧬🔬 It is unclear why the company is shutting down. 💔🏭 The closure will likely have an impact on the development of gene therapies. 🌍👥 Locanabio was focused on creating therapies for neurodegenerative diseases. 🧠💊
Moderna sets sights on 2025 for return to growth after COVID slump
📰 Moderna, a biotechnology company, plans to return to growth by 2025 after the COVID-19 pandemic setback. 🏭 The company expects that its mRNA platform will continue to be important in the development of new medicines. 💊 Moderna aims to expand its portfolio beyond COVID-19 vaccines and focus on other therapeutic areas. 🤝 Partnerships and collaborations with other companies will be crucial for Moderna's future growth. 💰 The company also plans to invest in manufacturing and infrastructure to support its growth strategy.
BioCina partners with GPN Vaccines against Streptococcus pneumoniae
📢 BioCina has partnered with GPN Vaccines to develop a vaccine against Streptococcus pneumoniae. 🔬💉 This partnership will leverage the expertise of both companies to accelerate the development of the vaccine. 🚀 Streptococcus pneumoniae is a common cause of pneumonia, meningitis, and other infections worldwide. 💊🌍 The vaccine will aim to prevent these infections and reduce the burden on healthcare systems. 💪🏥 By combining their resources, BioCina and GPN Vaccines hope to make a significant impact in the fight against Streptococcus pneumoniae. 🤝✨
With reworked gov grant, it’s back to business for Valneva Scotland plant
📰 The Valneva Scotland plant is back in business after receiving a reworked government grant. 💰 🏭 The plant, which specializes in biotechnology, had faced uncertainty after the European Commission terminated its COVID-19 vaccine contract. ❌ 🌱 However, the Scottish government has now amended its grant to support the plant's reopening. 💪 👥 This is good news for the local economy and the biotechnology industry. 🌍
